Purvalanol A

Purvalanol A is a potent CDK inhibitor, which inhibits cdc2-cyclin B, cdk2-cyclin A, cdk2-cyclin E, cdk4-cyclin D1, and cdk5-p35 with IC50s of 4, 70, 35, 850, 75 nM, resepctively.

Product Specifications

CAS Number

[212844-53-6]

Product Name Alternative

NG-60

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Apoptosis; Autophagy; CDK

Type

Reference compound

Related Pathways

Apoptosis; Autophagy; Cell Cycle/DNA Damage

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/Purvalanol-A.html

Concentration

10mM

Purity

98.61

Solubility

DMSO : ≥ 50 mg/mL|Ethanol : 10 mg/mL (ultrasonic)

Smiles

CC([C@@H](NC1=NC(NC2=CC=CC(Cl)=C2)=C3N=CN(C(C)C)C3=N1)CO)C

Molecular Formula

C19H25ClN6O

Molecular Weight

388.89

Precautions

H302, H315, H319, H335

References & Citations

[1]Gray NS, et al. Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. Science. 1998 Jul 24;281 (5376) :533-8.|[2]Bain J, et al. The specificities of protein kinase inhibitors: an update. Biochem J. 2003 Apr 1;371 (Pt 1) :199-204.|[3]Villerbu N, et al. Cellular effects of purvalanol A: a specific inhibitor of cyclin-dependent kinase activities. Int J Cancer. 2002 Feb 20;97 (6) :761-9.